Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-25-024024
Filing Date
2025-02-11
Accepted
2025-02-11 08:26:08
Documents
18
Period of Report
2024-11-26
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d935049d8ka.htm   iXBRL 8-K/A 33981
2 EX-23.1 d935049dex231.htm EX-23.1 1661
3 EX-99.2 d935049dex992.htm EX-99.2 116528
4 EX-99.3 d935049dex993.htm EX-99.3 101214
5 EX-99.4 d935049dex994.htm EX-99.4 161268
  Complete submission text file 0001193125-25-024024.txt   639660

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA xoma-20241126.xsd EX-101.SCH 4582
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE xoma-20241126_def.xml EX-101.DEF 14845
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE xoma-20241126_lab.xml EX-101.LAB 25308
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xoma-20241126_pre.xml EX-101.PRE 15943
21 EXTRACTED XBRL INSTANCE DOCUMENT d935049d8ka_htm.xml XML 8991
Mailing Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608
Business Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608 510-204-7239
XOMA Royalty Corp (Filer) CIK: 0000791908 (see all company filings)

EIN.: 522154066 | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39801 | Film No.: 25607751
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)